Real-world risperidone outcomes after schizophrenia relapse
About this title
Read the official source — NCT05480046Understand this study
What did researchers investigate?
This study evaluated the effectiveness of Risperidone ISM for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Aachen and 76 more locationsSee all locations and recruitment
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 275
- Sponsor
- Rovi Pharmaceuticals Laboratories
- Sponsor type
- Pharmaceutical company
- Study type
- Observational
- Intervention type
- Drug
- Locations
- United Kingdom, Germany, Italy, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT05480046
- Official title
Show the full official title
Risperidone ISM® Effectiveness in Schizophrenia Patients Hospitalised Due to A Relapse: a Prospective Non-interventional Evaluation (RESHAPE Study)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Aachen, Germany · Ansbach, Germany · Bayreuth, Germany
65 more locations
- Berlin, Germany
- Bonn, Germany
- Chemnitz, Germany
- Dortmund, Germany
- Eberswalde, Germany
- Essen, Germany
- Greifswald, Germany
- Hamburg, Germany
- Hemer, Germany
- Leipzig, Germany
- Mannheim, Germany
- Munich, Germany
- München, Germany
- Neustadt, Germany
- Werneck, Germany
- Ancona, Italy
- Bolzano, Italy
- Brescia, Italy
- Brindisi, Italy
- Crema, Italy
- Foggia, Italy
- Legnano, Italy
- Manfredonia, Italy
- Milan, Italy
- Montichiari, Italy
- Palermo, Italy
- Putignano, Italy
- Sant'Agata di Militello, Italy
- Vimercate, Italy
- Beja, Portugal
- Braga, Portugal
- Coimbra, Portugal
- Funchal, Portugal
- Guarda, Portugal
- Portimão, Portugal
- Porto, Portugal
- Santo Tirso, Portugal
- Tomar, Portugal
- Barcelona, Spain
- Burgos, Spain
- Córdoba, Spain
- Granada, Spain
- Huesca, Spain
- Jaén, Spain
- Jerez de la Frontera, Spain
- L'Hospitalet de Llobregat, Spain
- Las Palmas de Gran Canaria, Spain
- Lleida, Spain
- Lugo, Spain
- Madrid, Spain
- Majadahonda, Spain
- Manacor, Spain
- Manresa, Spain
- Mataró, Spain
- Móstoles, Spain
- Murcia, Spain
- Ourense, Spain
- Ponferrada, Spain
- Santander, Spain
- Talavera de la Reina, Spain
- Torrejón, Spain
- Úbeda, Spain
- Vigo, Spain
- Vitoria-Gasteiz, Spain
- London, United Kingdom
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the effectiveness of Risperidone ISM for people with schizophrenia.
Who is behind this study?
The study sponsor is Rovi Pharmaceuticals Laboratories, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Risperidone ISM.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
